Apathy and APOE4 are associated with reduced BDNF levels in alzheimer's disease

Journal of Alzheimer's Disease

Volumn 42, Issue 4, 2014, Pages 1347-1355

  Álvarez, Antón ^a,f   Aleixandre, Manuel ^b   Linares, Carlos ^c   Masliah, Eliezer ^d   Moessler, Herbert ^e  

^a Medinova Institute of Neurosciences   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c Complejo Asistencial HHSCJ ^*  (Spain)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e EVER Neuro Pharma   (Austria)

^f NONE   (Spain)

Author keywords

Alzheimer's disease; apathy; apolipoprotein E 4 allele; brain derived neurotrophic factor; elderly control subjects; mild cognitive impairment; serum

Indexed keywords

APOLIPOPROTEIN E EPSILON 4; APOLIPOPROTEIN E4; BRAIN DERIVED NEUROTROPHIC FACTOR; UNCLASSIFIED DRUG;

AGED; ALLELE; ALZHEIMER DISEASE; APATHY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPHORIA; FEMALE; GENE FREQUENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; BLOOD; GENETICS; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEXUAL DEVELOPMENT;

AGED; ALZHEIMER DISEASE; APATHY; APOLIPOPROTEIN E4; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; PSYCHIATRIC STATUS RATING SCALES; SEX CHARACTERISTICS;

EID: 84908013228     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140849     Document Type: Article

References (42)

1. Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD (2007) Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr Alzheimer Res 4, 340-350.
2. Ye X, Tai W, Zhang D (2012) The early events of Alzheimer's disease pathology: From mitochondrial dysfunction to BDNF axonal transport deficits. Neurobiol Aging 33, 1122. e1-10.
3. Ginsberg SD, Wuu J, Counts SE, Mufson EJ (2006) Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem 97, 475-487.
4. Lee J, Fukumoto H, Orne J, Klucken J, Raju S, Vanderburg CR, Irizarry MC, Hyman BT, Ingelsson M (2005) Decreased levels of BDNF protein in Alzheimer temporalcortex are independent of BDNF polymorphisms. Exp Neurol 194, 91-96.
5. Li G, Peskind ER, Millard SP, Chi P, Sokal I, Yu CE, Bekris LM, Raskind MA, Galasko DR, Montine TJ (2009) Cere-brospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One 4, e5424.
6. Peng S, Wuu J, Mufson EJ, Fahnestock M (2005) Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stagesof Alzheimer's disease. J Neurochem 93, 1412-1421.
7. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH (2009) Neuroprotec-tive effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15, 331-337.
8. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457, 981-989.
9. Forlenza OV, Diniz BS, Teixeira AL, Ojopi EB, Talib LL, Mendonça VA, Izzo G, Gattaz WF (2010) Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World J Biol Psychiatry 11, 774-780.
10. Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, Soekadar S, Richartz E, Koehler N, Bar-tels M, Buchkremer G, Schott K (2007) BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res 41, 387-394.
11. Lee JG, Shin BS, You YS, Kim JE, Yoon SW, Jeon DW, Baek JH, Park SW, Kim YH (2009) Decreased serum brain-derived neurotrophic factor levels in elderly korean with dementia. Psychiatry Investig 6, 299-305.
12. Yu H, Zhang Z, Shi Y, Bai F, Xie C, Qian Y, Yuan Y, Deng L (2008) Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han. J Clin Psychiatry 69, 1104-1111.
13. O'Bryant SE, Hobson V, Hall JR, Waring SC, Chan W, Massman P, Lacritz L, Cullum CM, Diaz-Arrastia R (2009) Texas Alzheimer's Research Consortium. Brain-derived neu-rotrophic factor levels in Alzheimer's disease. J Alzheimers Dis 17, 337-341.
14. O'Bryant SE, Hobson VL, Hall JR, Barber RC, Zhang S, Johnson L, Diaz-Arrastia R (2011) Texas Alzheimer's Research Consortium. Serum brain-derived neurotrophic factor levels are specifically associated with memory performance among Alzheimer's disease cases. Dement Geriatr Cogn Disord 31, 31-36.
15. Woolley JD, Strobl EV, Shelly WB, Miller BL, Mellon SH, Rankin KP (2012) BDNF serum concentrations show no relationship with diagnostic group or medication status in neurodegenerative disease. Curr Alzheimer Res 9, 815-821.
16. Angelucci F, Spalletta G, di Iulio F, Ciaramella A, Salani F, Colantoni L, Varsi AE, Gianni W, Sancesario G, Caltagirone C, Bossù P (2010) Alzheimer's disease (AD) and mild cognitive impairment (MCI) patients are characterizedby increased BDNF serum levels. Curr Alzheimer Res 7, 15-20.
17. Laske C, Stellos K, Hoffmann N, Stransky E, Straten G, Eschweiler GW, Leyhe T (2011) Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients. Int J Neuropsychopharmacol 14, 399-404.
18. Grünblatt E, Zehetmayer S, Bartl J, Löffler C, Wichart I, Rainer MK, Jungwirth S, Bauer P, Danielczyk W, Tragl KH, Riederer P, Fischer P (2009) Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITA study. J Psychiatr Res 43, 298-308.
19. Starkstein SE, Ingram L, Garau ML, Mizrahi R (2005) On the overlap between apathy and depression in dementia. J Neurol Neurosurg Psychiatry 76, 1070-1074.
20. Arlt S, Demiralay C, Tharun B, Geisel O, Storm N, Eichen-laub M, Lehmbeck JT, Wiedemann K, Leuenberger B, Jahn H (2013) Genetic risk factors for depression in Alzheimer's disease patients. Curr Alzheimer Res 10, 72-81.
21. Borroni B, Archetti S, Costanzi C, Grassi M, Ferrari M, Radeghieri A, Caimi L, Caltagirone C, Di Luca M, Padovani A, Working ITINAD, Group (2009) Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. Neurobiol Aging 30, 1406-1412.
22. Zhang L, Fang Y, Zeng Z, Lian Y, Wei J, Zhu H, Jia Y, Zhao X, Xu Y (2011) BDNF gene polymorphisms are associated with Alzheimer's disease-related depression and antidepres-sant response. J Alzheimers Dis 26, 523-530.
23. Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J, Voshaar RC, Elzinga BM (2011) Serum levels of brain-derived neurotrophic factor in major depressive disorder: State-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 16, 1088-1095.
24. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. American Psychiatric Association, Washington, DC.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of NINCDS-ADRDA Work Group. Neurology 34, 939-944.
26. Artero S, Petersen R, Touchon J, Ritchie K (2006) Revised criteria for mild cognitive impairment: Validation within a longitudinal population study. Dement Geriatr Cogn Disord 22, 465-470.
27. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6, 278-296.
28. Alvarez A, Cacabelos R, Sampedro C, Garcia-Fantini M, Aleixandre M (2007) Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging 18, 533-536.
29. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
30. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11, S13-S21.
31. Knopman DS, Knapp MJ, Gracon SI, Davis CS (1994) The Clinician Interview-Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease. Neurology 44, 2315-2321.
32. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: Comprehensive assessment of pychopathology in dementia. Neurology 44, 2308-2314.
33. Driscoll I, Martin B, An Y, Maudsley S, Ferrucci L, Mattson MP, Resnick SM (2012) Plasma BDNF isassociated with age-related white matter atrophy but not with cognitive function in older, non-demented adults. PLoS One 7, e35217.
34. Komulainen P, Pedersen M, Hänninen T, Bruunsgaard H, Lakka TA, Kivipelto M, Hassinen M, Rauramaa TH, Pedersen BK, Rauramaa R (2008) BDNF is a novel marker of cognitive function in ageing women: The DR's EXTRA Study. Neurobiol Learn Mem 90, 596-603.
35. Chu CL, Liang CK, Chou MY, Lin YT, Pan CC, Lu T, Chen LK, Chow PC (2012) Decreased plasma brain-derived neurotrophic factor levels in institutionalized elderly with depressive disorder. J Am Med Dir Assoc 13, 434-437.
36. Dreimüller N, Schlicht KF, Wagner S, Peetz D, Borysenko L, Hiemke C, Lieb K, Tadić A (2012) Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with major depression. Neuropharmacology 62, 264-269.
37. Bus BA, Tendolkar I, Franke B, de Graaf. J, Heijer MD, Buitelaar JK, Oude Voshaar RC (2012) Serum brain-derived neurotrophic factor: Determinants and relationship with depressive symptoms in a community population of middle-aged and elderly people. World J Biol Psychiatry 13, 39-47.
38. Nagata T, Shinagawa S, Nukariya K, Yamada H, Nakayama K (2012) Association between BDNF polymorphism (Val66Met) and executive function in patients with amnestic mild cognitive impairment or mild Alzheimer disease. Dement Geriatr Cogn Disord 33, 266-272.
39. Tschanz JT, Corcoran CD, Schwartz S, Treiber K, Green RC, Norton MC, Mielke MM, Piercy K, Steinberg M, Rabins PV, Leoutsakos JM, Welsh-Bohmer KA, Breitner JC, Lyketsos CG (2011) Progression of cognitive, functional, and neu-ropsychiatric symptom domains in a population cohort with Alzheimer dementia: The Cache County Dementia Progression study. Am J Geriatr Psychiatry 19, 532-342.
40. Fukumoto N, Fujii T, Combarros O, Kamboh MI, Tsai SJ, Matsushita S, Nacmias B, Comings DE, Arboleda H, Ingels-son M, Hyman BT, Akatsu H, Grupe A, Nishimura AL, Zatz M, Mattila KM, Rinne J, Goto YI, Asada T, Nakamura S, Kunugi H (2009) Sexually dimorphic effect of the Val66Met polymorphism of BDNF on susceptibility to Alzheimer's disease: New data and meta-analysis. Am J Med Genet B Neuropsychiatr Genet 153B, 235-242.
41. Elfving B, Buttenschøn HN, Foldager L, Poulsen PH, Andersen JH, Grynderup MB, Hansen AM, Kolstad HA, Kaerlev L, Mikkelsen S, Thomsen JF, Børglum AD, Wegener G, Mors O (2012) Depression, the Val66Met polymorphism, age, and gender influence the serum BDNF level. J Psychiatr Res 46, 1118-1125.
42. Hashimoto R, Hirata Y, Asada T, Yamashita F, Nemoto K, Mori T, Moriguchi Y, Kunugi H, Arima K, Ohnishi T (2009) Effect of the brain-derived neurotrophic factor and the apolipoprotein E polymorphisms on disease progression in preclinical Alzheimer's disease. Genes Brain Behav 8, 43-52.